Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care products and services to office-based dental and medical practitioners, announced today that its board of directors has authorized the repurchase of up to $750 million of shares of the company’s common stock.
This program is in addition to the $500 million repurchase program announced in January 2025, which is anticipated to be fully executed by the end of the first quarter of 2026.
The company had approximately 118.6 million shares outstanding as of September 8, 2025. This new authorization represents approximately 9.0 percent of shares outstanding at the current stock price. Purchases may be made from time to time in the open market or through negotiated transactions.
“Henry Schein’s decision to repurchase shares reflects the confidence we have in our 2025–2027 BOLD+1 strategic plan and its potential to deliver sustainable growth and value,” said Ronald N. South, senior vice president and chief financial officer. “With the support of a strong balance sheet, we are well positioned to serve our markets and further expand the depth and reach of our health care solutions.”
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes.
Our business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.
A Fortune 500 company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The company’s sales reached $12.7 billion in 2024 and have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995.
Source: www.henryschein.com
News 14 November 2025
Henry Schein One and AWS Collaborate to Transform Global Dentistry with Generative AI
Industry leaders join forces to bring advanced AI capabilities to dental technology platforms — redefining patient care, clinical efficiency, and practice performance worldwide
News 13 November 2025
VideaHealth, the leading dental AI platform, in collaboration with Henry Schein One, today announced the launch of the Impact Panel, a new enhancement within the Detect AI experience for Dentrix and...
Products 13 October 2025
Henry Schein’s 28th annual ‘Back to School’ programme supports students worldwide
With backpacks full of supplies, team Schein helps equip children to thrive in the classroom
Products 25 August 2025
Oral Genome, a leading innovator in salivary testing, today announced a strategic partnership with Henry Schein, the world’s largest provider of healthcare solutions to office-based dental and...
News 14 August 2025
ACCLEAN’s lightweight design and intuitive controls offer comfort mixed with high performance.
Prosthodontics 17 November 2025
The purpose of this report is to describe a new technique to fabricate and deliver an implant-supported fixed prosthesis to the patient on the day of surgery, and to propose a protocol for the...
Editorials 17 November 2025
The Langkamp Allison Award recognizes a Pitt Dental Medicine third-year dental student interested in pursuing a career in dental education.
Products 17 November 2025
VELMENI today unveiled VELMENI Voice, an AI-driven voice recognition tool designed to transform periodontal charting and clinical documentation.
News 17 November 2025
Angelalign Technology Inc. (6699.HK) (“Angel”) recently announced the expansion of its flexible iOrtho platform to include direct integration with the Dexis, Shining 3D, and Panda scanners.
News 17 November 2025
Following the first FDA clearance for technology that measures internal mobility in teeth, Perimetrics CEO and Chairman Robert Hayman is once again leading dentistry into a new era with InnerView, a...